Patent US3565708A successfully refreshed from Google Patents.
Patent US6129757A successfully refreshed from Google Patents.
US6129757A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implantable members for receiving therapeutically useful compositions
Assignee: Boston Scientific Scimed Inc
•
Filing: 1998-05-18
•
Granted: 2000-10-10
•
Expires: 2018-05-18
Abstract
Abstract An implantable prosthesis includes a porous polymeric member having pores present in its wall structure wherein these pores contain a variety of therapeutically useful compositions including, collagen, genetically altered cells and piezoelectric materials. A process of preparing such a prosthesis is also disclosed.
Inventors
- 👤 Kevin Weadock
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 16:48
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3808; A61L27/50; A61L27/54; A61L27/56; A61L2300/00; A61L2300/10; A61L2300/102; A61L2300/104; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/408; A61L2300/416; A61L2300/42; A61L2300/44; A61L2300/60; A61L2300/64; Y; Y10; Y10S; Y10S623/00; Y10S623/901
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
50 words
An implantable member comprising a porous polymeric substrate having a wall structure substantially free of ePTFE nodes and fibrils structure, said wall structure having pores filled with a fluid composition that contains one or more substances which are precipitated out in situ to form an insoluble, biocompatible, biodegradable material therein.
Claim 2
Dependent Claim
50 words
An implantable member comprising a porous polymeric substrate having a wall structure substantially free of ePTFE nodes and fibrils structure, said wall structure having pores filled with a fluid composition that contains one or more substances which are precipitated out in situ to form an insoluble, biocompatible, biodegradable material therein.
Claim 3
Dependent Claim
50 words
The implantable member of claim 1, wherein said substances are selected from the group consisting of thrombo-resistant agents, antibiotic agents, anti-tumor agents, growth hormones, antiviral agents, anti-angiogenic agents, angiogenic agents, anti-mitotic agents, anti-inflammatory agents, cell cycle regulating agents, genetic agents, hormones, their homologs, derivatives, fragments, pharmaceutical salts, and combinations thereof.
Claim 4
Dependent Claim
44 words
The implantable member of claim 2, wherein said thrombo-resistant agents are selected from the group consisting of heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, lytic agents, including urokinase and streptokinase their homologs, analogs, fragments, derivatives and pharmaceutical salts thereof.
Claim 5
Dependent Claim
38 words
The implantable member of claim 2, wherein said antibiotic agents are selected from the group consisting of penicillins, cephalosporins, vancomycins, aminoglycosides, quinolones, polymyxins, erythromycins, tetracyclines, chloramphenicols, clindamycins, lincomycins, sulfonamides their homologs, analogs, derivatives, pharmaceutical salts and mixtures thereof.
Claim 6
Dependent Claim
87 words
The implantable member of claim 2, wherein said anti-tumor agents are selected from the group consisting of paclitaxel, docetaxel, alkylating agents including mechlorethamine, chlorambucil, cyclophosphamide, melphalan and ifosfamide; antimetabolites including methotrexate, 6-mercaptopurine, 5-fluorouracil and cytarabine; plant alkaloids including vinblastine, vincristine and etoposide; antibiotics including doxorubicin, daunomycin, bleomycin, and mitomycin; nitrosureas including carmustine and lomustine; inorganic ions including cisplatin; biological response modifiers including interferon; angiostatin agents and endostatin agents; enzymes including asparaginase; and hormones including tamoxifen and flutamide their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.
Claim 7
Dependent Claim
38 words
The implantable member of claim 2, wherein said anti-viral agents are selected from the group consisting of amantadines, rimantadines, ribavirins, idoxuridines, vidarabines, trifluridines, acyclovirs, ganciclovirs, zidovudines, foscarnets, interferons their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.
Claim 8
Dependent Claim
40 words
The implantable member of claim 1, wherein said polymeric substrate is selected from the group consisting of polyurethanes, polycarbonates, polyethylenes, polypropylenes, polyvinyl chlorides, polyvinyl acetates, polystyrenes, polyureas, silicone rubbers, polyamides, polyaldehydes, natural rubbers, polyether-ester copolymers, styrene-butadiene copolymers, and combinations thereof.
Claim 9
Dependent Claim
14 words
The implantable member of claim 1, wherein said insoluble, biocompatible, biodegradable material includes gelatin.
Claim 10
Dependent Claim
16 words
The implantable member of claim 1, wherein said insoluble, biocompatible, biodegradable material includes extracellular matrix proteins.
Claim 11
Dependent Claim
48 words
The implantable member of claim 9, wherein said extracellular matrix proteins are selected from the group consisting of collagen, including collagen Type I, collagen Type II, collagen Type III, collagen Type IV, and collagen Type V, vitronectin, fibronectin, laminin, reconstituted basement membrane matrices, and derivatives and mixtures thereof.
Claim 12
Dependent Claim
27 words
The implantable member of claim 1, wherein a surface of said polymeric substrate is subjected to a silver ion-beam-assisted deposition process to render said substrate more antimicrobial.
Claim 13
Dependent Claim
29 words
The implantable member of claim 11, wherein silver is deposited onto said substrate via said ion-beam-assisted deposition process prior to filling said pores with said insoluble, biocompatible, biodegradable material.
References Cited (Backward Citations)
GB153685A
Cited
US3276448A
Cited
US3400719A
Cited
DE1494939A1
Cited
DE1491218A1
Cited
US3483016A
Cited
FR1601323A
Cited
FR2029155A5
Cited
US3953566A
Cited
US3962153A
Cited
US4233360A
Cited
US4921495A
Cited
US5034265A
Cited
FR2558720A1
Cited
US4842575A
Cited
US5197977A
Cited
US5037377A
Cited
EP0230635A2
Cited
US4822361A
Cited
EP0237037A2
Cited
US4784659A
Cited
US5131907A
Cited
US5028597A
Cited
US4871361A
Cited
US5030225A
Cited
US4966999A
Cited
US5536656A
Cited
US5141522A
Cited
US5290271A
Cited
WO1992000110A1
Cited
US5468562A
Cited
US5520664A
Cited
EP0531547A1
Cited
US5192310A
Cited
US5474797A
Cited
US5246452A
Cited
US5492763A
Cited
EP0596615A1
Cited
WO1994024298A1
Cited
CA2169638A1
Cited
US5665114A
Cited
US5716660A
Cited
WO1996008149A1
Cited
US5624704A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-10-10 | 2004-04-10 | 2004-10-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-10-10 | 2008-04-10 | 2008-10-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-10-10 | 2012-04-10 | 2012-10-10 | $7700.00 | Window Closed / Lapsed |